Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

Ares Management and New Leaf Venture Partners Commit To Purchase

Convertible Notes in New Subsidiary of $200 to $300 Million

Transaction Proceeds to be Used to Reduce Angiotech Debt

VANCOUVER, July 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that Angiotech's Board of Directors has authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions, Inc. ("API"). Angiotech will contribute to API certain business assets and intellectual property, which include primarily business assets of Angiotech other than the intellectual property and royalty revenue related to the TAXUS(R) coronary stent system. The Company has entered into a note purchase agreement with Ares Management and New Leaf Venture Partners, under which the investors will purchase between $200 and $300 million, at the Company's option, of convertible notes issued by API that will be convertible into a significant minority equity interest in API. Angiotech and its shareholders will benefit from the future performance of API based on retaining a significant continuing equity interest in the newly formed subsidiary. The net proceeds from the issuance of the convertible notes will be used to reduce Angiotech's existing debt, pursuant to tender offers announced and commenced concurrent with this announcement. The transaction is subject to approval of the Company's shareholders and other customary closing conditions.

"We are pleased to announce a transaction today that we believe offers significant immediate value and risk mitigation for our shareholders and bondholders, while retaining significant partic
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... BEIJING , May 17, 2013  Yongye International, ... "Company"), a leading developer, manufacturer, and distributor of crop ... China , today announced that, on May 16, ... board of directors (the "Board of Directors") was provided ... ( Hong Kong ) Limited ("Abax") to ...
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
(Date:5/16/2013)... ISPE announced today that ... the newly created position of Vice President of ... be responsible for stimulating ISPE’s revenue growth by ... Society’s Member-led and staff-driven business model, initiating integrated ... membership and product marketing. , “Barbara joins ISPE ...
(Date:5/16/2013)... 2013 Kitware , a ... announces new Phase II SBIR funding from the ... of an open-source, high performance computing (HPC) simulation ... enables researchers to select only the toolkits and ... computation, or analysis tasks. , Manufacturers increasingly ...
Breaking Biology Technology:Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2
... Conference on Health Informatics (HEALTHINF 2009) will feature OpenClinica in a ... is Ripe" , ... Porto, Portugal (PRWEB) January 8, ... the upcoming International Conference on Health Informatics (HEALTHINF 2009) January 14-17, ...
... SAN CARLOS, Calif., Jan. 7 Nuvelo, Inc.,(Nasdaq: ... stockholders of Nuvelo have approved,the issuance of Nuvelo ... 24, 2008, as amended, between Nuvelo, ARCA biopharma ... adjourn Nuvelo,s special,stockholder meeting until January 23, 2009, ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) will ... on Wednesday, January 14, at 3:00 pm PST at the ... be accessible through the J.P. Morgan website at http://metameetings.com/webcasts/jpmorgan/healthcare09 ... www.parpharm.com . A replay will be available for approximately ...
Cached Biology Technology:OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 4Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 5
(Date:5/17/2013)... of a group of proteins in the brain responsible ... new target that could increase cell survival. , The ... Biochemistry and published in the EMBO journal ... to new therapies for stroke and other brain diseases. ... team which identified a protein, known as SUMO, responsible ...
(Date:5/17/2013)... Sustainable Global Logistics Operations) is aiming to cut CO2 ... intermodal loading systems and the boosting of intelligent systems ... with experience in the logistics sector and in supply ... a duration of three and a half years. , ... components and ontologies shared by the users, objects and ...
(Date:5/17/2013)... for Experimental Biology (FASEB) released a new analysis ... highlighting the devastating impact of sequestration on the nation,s ... a May 15th Senate Appropriations Committee hearing featuring NIH ... $1.6 billion cut the agency sustained in FY 2013 ... the scientific community." , According to data from ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... the Arctic Ocean warms this century, shellfish, snails and ... invasion of the northern Atlantic that was interrupted by ... professor of geology at the University of California, Davis, ... Climate models predict a nearly ice-free Arctic Ocean ...
... College of Pharmacy researchers have discovered a marine compound ... cell growth in laboratory tests, a finding they hope ... battle the disease. The UF-patented compound, largazole, is ... who described results from early studies today (Aug. 7) ...
... of health and human performance is launching an international effort ... habits and physical activity. The study will take place ... , ... Texas Obesity Research Center,s (TORC) International Health Challenge, and offers ...
Cached Biology News:Pacific shellfish ready to invade Atlantic 2Researchers find cancer-inhibiting compound under the sea 2Researchers find cancer-inhibiting compound under the sea 3TORC at UH turns to virtual world of Second Life for new study 2
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... plate, Directly compatible with ABI thermal cyclers, ... improved sealing characteristics can be sealed ... cap strips, Certified free of DNase, RNase ... of Thermo Fisher Scientific, the world leader ...
BD BioCoat Vented Caps for 175 cm2 Flasks...
Biology Products: